Compare Ginkgo Bioworks Holdings Inc (DNA) vs Flux Power Holdings Inc (FLUX) Price & Performance

Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.

DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.

FLUX trades at $0.47, down 3.96% today, with bearish technical signals from moving averages. The company reported Q4 2026 revenue of $8.2M, beating expectations, but posted a net loss of $6.67M for 2025. Recent news highlights a rejected acquisition proposal from Solidion Technology. Despite negative profitability metrics, all six covering analysts maintain Buy ratings.

FLUX faces significant execution risks with negative margins and cash flow challenges, but analyst consensus remains bullish. The stock's current valuation at 0.22 P/S suggests potential upside if operational improvements materialize. Key risks include sustained losses and competitive pressures in the energy storage sector.